The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Letrozole, an aromatase inhibitor, is ineffective in the presence of ovarian estrogen production. Two subpopulations of apparently postmenopausal women might derive reduced benefit from letrozole due to residual or returning ovarian activity: younger women (who have the potential for residual subcli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Chirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thürlimann, Beat, Ejlertsen, Bent, Bonnefoi, Hervé, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802157/
https://ncbi.nlm.nih.gov/pubmed/21892704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1741-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados